Company profile
MAIA BIOTECHNOLOGY, INC.
AMEX:MAIABiotechnology: Pharmaceutical Preparations
Drug pipeline (7)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ANGIOMAX RTU | approved | — | 0 | — |
| BACLOFEN | approved | — | 0 | — |
| BORTEZOMIB | approved | — | 30 | approved |
| DAPTOMYCIN | approved | — | 0 | — |
| LEVOTHYROXINE SODIUM | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06908304 | phase3 | recruiting | 2025-12-08 | 2027-07-31 | Maia Biotechnology | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC |
| NCT05208944 | phase2 | active_not_recruiting | 2022-06-08 | 2027-09-30 | Maia Biotechnology | THIO Sequenced With Cemiplimab in Advanced NSCLC |
FDA applications (10)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 217630 | 2024-11-21 | NDA | MAIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 210850 | 2022-11-22 | NDA | MAIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 215331 | 2022-07-27 | NDA | MAIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 215025 | 2021-06-10 | NDA | MAIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 210048 | 2019-09-11 | ANDA | MAIA PHARMACEUTICALS INC | |||||
Loading… | ||||||||